24880
5-氯-7-碘-8-羟基喹啉
≥95.0% (HPLC)
别名:
5-氯-8-羟基-7-碘喹啉, 氯碘喹啉, 氯碘羟喹
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H5ClINO
化学文摘社编号:
分子量:
305.50
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
204-984-4
Beilstein/REAXYS Number:
153637
MDL number:
Assay:
≥95.0% (HPLC)
Form:
powder
InChI key
QCDFBFJGMNKBDO-UHFFFAOYSA-N
InChI
1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
SMILES string
Oc1c(I)cc(Cl)c2cccnc12
assay
≥95.0% (HPLC)
form
powder
solubility
dioxane: soluble 0.5 g/10 mL, clear, faintly yellow to yellow
functional group
chloro, iodo
Quality Level
General description
5-Chloro-7-iodo-8-quinolinol is an antibiotic with metal-binding properties and exhibits anticancer activity in vitro and in vivo. 5-Chloro-7-iodo-8-quinolinol, its glucuronide and sulfate in serum, urine and milk has been quantitated by gas chromatography.
Application
5-Chloro-7-iodo-8-quinolinol has been used in analysis of intracellular free zinc ions with the FluoZin-3 probes using fluorescence microscopy.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
A gas chromatographic determination method of 5-chloro-7-iodo-8-quinolinol and its conjugates in biological fluids.
C Chen et al.
Chemical & pharmaceutical bulletin, 24(1), 97-101 (1976-01-01)
Alessio Innocenti et al.
Bioorganic & medicinal chemistry letters, 18(5), 1583-1587 (2008-02-05)
The inhibition of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) with three phenols was investigated. Phenol was an effective CA I-IV, IX, XII and XIV inhibitor (K(I)s of 2.7-11.5 microM) and a less effective one against the other isoforms, CA
Silvio R Bareggi et al.
CNS neuroscience & therapeutics, 18(1), 41-46 (2011-01-05)
Clioquinol was produced as a topical antiseptic and marketed as an oral intestinal amebicide in 1934, being used to treat a wide range of intestinal diseases. In the early 1970s, it was withdrawn from the market as an oral agent
Peter J Crouch et al.
Journal of neurochemistry, 119(1), 220-230 (2011-07-30)
Impaired metal ion homeostasis causes synaptic dysfunction and treatments for Alzheimer's disease (AD) that target metal ions have therefore been developed. The leading compound in this class of therapeutic, PBT2, improved cognition in a clinical trial with AD patients. The
Lin W Hung et al.
Future medicinal chemistry, 4(8), 955-969 (2012-06-02)
In 1906, Alois Alzheimer first characterized the disease that bears his name. Despite intensive research, which has led to a better understanding of the pathology, there is no effective treatment for this disease. Of the drugs approved by the US
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持